Tinlarebant - Belite Bio
Alternative Names: aka LBS-008; BPN-14967; LBS-008Latest Information Update: 04 Dec 2025
At a glance
- Originator Columbia University
- Developer Belite Bio
- Class Eye disorder therapies; Fluorinated hydrocarbons; Ketones; Piperidines; Pyrazoles; Pyridines; Small molecules
- Mechanism of Action RBP4 protein inhibitors
-
Orphan Drug Status
Yes - Stargardt disease
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Dry macular degeneration; Stargardt disease
Most Recent Events
- 01 Dec 2025 Adverse events data from a phase III DRAGON trial in Stargardt disease released by Belite Bio
- 02 Nov 2025 UK's MHRA agrees to accept Conditional Marketing Authorization application for Tinlarebant for the treatment of Stargardt disease
- 15 Oct 2025 Center for Drug Evaluation of NMPA agrees to accept the NDA with priority review for tinlarebant for Stargardt disease